Browse hierarchy: [Microbiology (MI)](/submissions/MI) → [Subpart D — Serological Reagents](/submissions/MI/subpart-d%E2%80%94serological-reagents) → [21 CFR 866.3390](/submissions/MI/subpart-d%E2%80%94serological-reagents/866.3390) → LIC — Antiserum, Coagglutination (Direct) Neisseria Gonorrhoeae

# LIC · Antiserum, Coagglutination (Direct) Neisseria Gonorrhoeae

_Microbiology · 21 CFR 866.3390 · Class 2_

**Canonical URL:** https://fda.innolitics.com/submissions/MI/subpart-d%E2%80%94serological-reagents/LIC

## Overview

- **Product Code:** LIC
- **Device Name:** Antiserum, Coagglutination (Direct) Neisseria Gonorrhoeae
- **Regulation:** [21 CFR 866.3390](/submissions/MI/subpart-d%E2%80%94serological-reagents/866.3390)
- **Device Class:** 2
- **Review Panel:** [Microbiology](/submissions/MI)
- **3rd-party reviewable:** yes

## Identification

Neisseria spp. direct serological test reagents are devices that consist of antigens and antisera used in serological tests to identify Neisseria spp. from cultured isolates. Additionally, some of these reagents consist of Neisseria spp. antisera conjugated with a fluorescent dye (immunofluorescent reagents) which may be used to detect the presence of Neisseria spp. directly from clinical specimens. The identification aids in the diagnosis of disease caused by bacteria belonging to the genus Neisseria, such as epidemic cerebrospinal meningitis, meningococcal disease, and gonorrhea, and also provides epidemiological information on diseases caused by these microorganisms. The device does not include products for the detection of gonorrhea in humans by indirect methods, such as detection of antibodies or of oxidase produced by gonococcal organisms.

## Classification Rationale

Class II (performance standards).

## Recent Cleared Devices (9 of 9)

| Record | Device Name | Applicant | Decision Date | Decision |
| --- | --- | --- | --- | --- |
| [K921075](https://fda.innolitics.com/submissions/MI/subpart-d%E2%80%94serological-reagents/LIC/K921075.md) | PHADEBACT MONOCLONAL GC TEST, MODIFICATION | Karo Bio Diagnostics AB | May 22, 1992 | SESE |
| [K911430](https://fda.innolitics.com/submissions/MI/subpart-d%E2%80%94serological-reagents/LIC/K911430.md) | IDEIA(TM) CHLAMYDIA, MODIFICATION | Novo Nordisk Diagnostics, Ltd. | Aug 7, 1991 | SESE |
| [K880076](https://fda.innolitics.com/submissions/MI/subpart-d%E2%80%94serological-reagents/LIC/K880076.md) | G-MARK | Bainbridge Laboratories, Inc. | Jul 1, 1988 | SESE |
| [K874078](https://fda.innolitics.com/submissions/MI/subpart-d%E2%80%94serological-reagents/LIC/K874078.md) | MERITEC(TM)-GC | Meridian Diagnostics, Inc. | Dec 9, 1987 | SESE |
| [K871105](https://fda.innolitics.com/submissions/MI/subpart-d%E2%80%94serological-reagents/LIC/K871105.md) | THE GONOGEN II TEST KIT FOR NEISSERIA GONORRHOEAE | New Horizons Diagnostics Co. | May 13, 1987 | SESE |
| [K851650](https://fda.innolitics.com/submissions/MI/subpart-d%E2%80%94serological-reagents/LIC/K851650.md) | PHADEBACT MONOCLONAL GC OMNI TEST | Pharmacia, Inc. | Jul 12, 1985 | SESE |
| [K850351](https://fda.innolitics.com/submissions/MI/subpart-d%E2%80%94serological-reagents/LIC/K850351.md) | PHADEBACT MONOCLONAL GC TEST | Pharmacia, Inc. | Mar 13, 1985 | SESE |
| [K821362](https://fda.innolitics.com/submissions/MI/subpart-d%E2%80%94serological-reagents/LIC/K821362.md) | IMPROVED GONO GEN | New Horizons Diagnostics Co. | Aug 4, 1982 | SESE |
| [K820007](https://fda.innolitics.com/submissions/MI/subpart-d%E2%80%94serological-reagents/LIC/K820007.md) | NEISSERIA GONORRHOEAE TEST | New Horizons Diagnostics Co. | Jan 29, 1982 | SESE |

## Top Applicants

- New Horizons Diagnostics Co. — 3 clearances
- Pharmacia, Inc. — 2 clearances
- Bainbridge Laboratories, Inc. — 1 clearance
- Karo Bio Diagnostics AB — 1 clearance
- Meridian Diagnostics, Inc. — 1 clearance

---

**Source:** [https://fda.innolitics.com/submissions/MI/subpart-d%E2%80%94serological-reagents/LIC](https://fda.innolitics.com/submissions/MI/subpart-d%E2%80%94serological-reagents/LIC)

**Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact).

**Cite:** Innolitics at https://innolitics.com